Bouribab Amal, Errougui Abdelkbir, Chtita Samir
Laboratory of Analytical and Molecular Chemistry, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca, Casablanca, Morocco.
Curr Top Med Chem. 2025;25(10):1141-1164. doi: 10.2174/0115680266312422240712053821.
Growth factors and their receptor tyrosine kinases play a central role in regulating vital cellular processes such as proliferation, differentiation, division, and cell survival, and they are closely associated with the development of various types of cancer, particularly in the context of angiogenesis. Although several small chemical compounds targeting tyrosine kinase receptors have been approved by the FDA for cancer treatment by inhibiting angiogenesis, there is still a need for more effective medications. studies are now crucial tools for the design of new drugs, offering considerable advantages such as cost and time reduction. In this review, we examined recent research carried out between 2022 and 2024, focusing on new drug candidates synthesized to fight cancer, in particular by targeting tyrosine kinase receptors involved in the process of angiogenesis.
生长因子及其受体酪氨酸激酶在调节细胞增殖、分化、分裂和细胞存活等重要细胞过程中发挥着核心作用,并且它们与各类癌症的发展密切相关,尤其是在血管生成方面。尽管几种靶向酪氨酸激酶受体的小分子化合物已被美国食品药品监督管理局(FDA)批准用于通过抑制血管生成来治疗癌症,但仍需要更有效的药物。研究现在是新药设计的关键工具,具有降低成本和时间等诸多优势。在本综述中,我们研究了2022年至2024年间进行的最新研究,重点关注为对抗癌症而合成的新候选药物,特别是通过靶向参与血管生成过程的酪氨酸激酶受体。